Lyka Labs share price
NSE: LYKALABSBSE: 500259Pharmaceuticals & BiotechnologySmall Cap
Last close ₹80.99down ₹1.65 (2.00%)BSE ₹83.54
Share price at the NSE close on 23 Oct 2026. Previous close ₹82.64.
52-week range of traded prices to 23 Oct 2026
₹44.10Low, 30 Mar 2026₹98.90High, 24 Oct 2025
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Next results date: the board meets on 30 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹293 Cr2,310th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 25 May 2026
- 3.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- −9.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- −8.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 25 May 2026
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day.
- 4,265
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter. Net profit is left blank for Mar 2022: the profit stated for the year is its quarters' profit belonging to the company's shareholders added up, which leaves out the other owners' share those quarters state, so the group's profit is not stated.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 10 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹42 Crup 50.94%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹2.05 CrQuarter to Mar 2026: −₹8.07 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 4.8%
Revenue by year
Peak revenue ₹194 Cr, year to Mar 2022
Net profit by year, a loss in red
- Net profit
- Loss
A loss in the year to Mar 2026, −₹10 CrA loss in 8 of the 9 years with results on record
| ₹ crore | Sep 2024Filed 12 Nov | Dec 2024Filed 4 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 1 Aug | Sep 2025Filed 13 Nov | Dec 2025Filed 29 Jan | Mar 2026Filed 25 May | Jun 2026Filed 10 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 41.2 | 33.8 | 33.4 | 33.0 | 36.7 | 30.7 | 28.0 | 42.3 |
| Net profit | 2.1 | 2.7 | 2.0 | 1.0 | −3.2 | −0.2 | −8.1 | 2.0 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 5.1% | 8.0% | 6.1% | 3.0% | −8.8% | −0.5% | −28.8% | 4.8% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharma, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months. Not shown, EV/EBITDA: operating loss, last twelve months. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 23% of 933 trading days over the last 5 years.
LowestHighest
Its median5.6Industry median2.8
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −55.2% | – | – | 0.0% |
| 3 years | −24.5% | – | – | 0.0% |
| 5 years | +11.5% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Lyka Labs in market cap. 1 company in the table last traded before then: its row is priced on its last trade.
Lyka Labs is not on the chart: it has no P/E today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Jenburkt PharmaceuticalsJENBURPH | 384 | 11.7 | 2.0 | 8.1 | +9.1% | +1.2% | 17.8% | 19.2% | 2.38% |
 Medicamen BiotechMEDICAMEQ | 344 | – | 1.2 | 18.5 | +24.7% | – | – | 3.7% | 0.39% |
 Aarey Drugs & PharmaceuticalsAAREYDRUGS | 340 | – | – | – | −7.7% | – | – | 1.8% | 0.00% |
 Astonea LabsASTONEALAB | 340 | 75.2 | 5.9 | – | – | – | 12.0% | – | 0.00% |
 Astal LaboratoriesASTALLTD | 279 | 28.7 | 0.9 | 19.3 | +122.7% | +4.4% | 5.4% | 4.2% | 0.00% |
 Ambalal Sarabhai EnterprisesAMBALALSA | 266 | 19.6 | 1.7 | 20.1 | +4.9% | +5.8% | 9.1% | 5.0% | 0.00% |
 Zenotech LaboratoriesZENOTECH | 246 | – | 2.6 | 61.1 | +4.6% | – | −2.6% | −3.9% | 0.00% |
 BDH IndustriesBDH | 244 | 20.8 | 3.2 | 14.2 | +44.8% | +22.9% | 16.1% | 18.2% | 1.18% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Aug 2026
11 Aug · Meeting
11 Aug · Results
10 Aug · Meeting
Lyka Labs share price by year
Each calendar year to 2025.Lyka Labs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 75.89 | −51.9% | 163.50 | 74.04 |
| 2024 | 157.82 | +27.5% | 172.97 | 101.25 |
| 2023 | 123.75 | −4.6% | 151.80 | 89.75 |
| 2022 | 129.70 | −41.7% | 249.60 | 104.45 |
| 2021 | 222.30 | +617.1% | 254.30 | 22.55 |
| 2020 | 31.00 | +58.2% | 31.00 | 10.45 |
| 2019 | 19.60 | −35.4% | 34.55 | 15.05 |
| 2018 | 30.35 | −52.9% | 77.95 | 26.90 |
| 2017 | 64.40 | +20.8% | 67.45 | 41.25 |
| 2016 | 53.30 | −58.4% | 130.05 | 49.25 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 80.99 | 80.99 | 80.99 | 80.99 | 80.99 | 4,265 |
| 22 Oct 2026 | 82.64 | 82.64 | 82.64 | 82.64 | 82.64 | 6,362 |
| 21 Oct 2026 | 84.32 | 84.32 | 84.32 | 84.32 | 84.32 | 2,536 |
| 19 Oct 2026 | 86.04 | 86.04 | 86.04 | 86.04 | 86.04 | 17,161 |
| 16 Oct 2026 | 87.79 | 87.79 | 87.79 | 87.79 | 87.79 | 47,097 |
| 15 Oct 2026 | 82.00 | 83.61 | 82.00 | 83.61 | 83.45 | 93,279 |
| 14 Oct 2026 | 74.10 | 79.63 | 74.00 | 79.63 | 78.78 | 78,450 |
| 13 Oct 2026 | 74.90 | 75.84 | 74.90 | 75.84 | 75.72 | 34,860 |
| 12 Oct 2026 | 73.78 | 73.79 | 71.26 | 72.23 | 72.22 | 8,515 |
| 9 Oct 2026 | 72.45 | 74.80 | 70.50 | 72.65 | 72.88 | 25,329 |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Lyka Labs Limited
- NSE symbol
- LYKALABS
- BSE code
- 500259
- ISIN
- INE933A01014
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jun 1986 on BSE, Feb 1995 on NSE
- Face value
- ₹10
- CIN
- L24230GJ1976PLC008738
- Corporate identity number, the registrar of companies' code for it